How Endologix Renewed One Doctor & #039;s Confidence in the Ovation Device

It's been a turbulent couple of years for Endologix, but as MD+DI reported in February, the company has been working hard to win back customers. During the company's first-quarter earnings call, CEO John Onopchenko shared a story about a physician at an academic medical center in the Western United States (he did not disclose the name of the physician or the center) who had used Ovation only twice over the course of 2017 and 2018.  Irvine, CA-based Endologix acquired the Ovation platform through its merger with TriVascular in February 2016. It's a low-profile device that has broadened the company's portfolio in terms of patients that can be treated. In June 2017, Endologix reported positive 30-day results from a study evaluating EVAR in women using the Ovation system. "His reasons for not using it more frequently were that there were limited data available and he believed it to be a technically challenging product to deploy," Onopchenko said. "And frankly, he chose as those initial cases, really a challenging reverse-tapered-neck presentation." Late last year, Endologix initiated multiple conversations with this doctor to explain the "why" behind the design of Ovation, along with new evidence in the form of five-year ENCORE data, and those conversations intrigued the doctor enough to spend a day visiting the company's Santa Rosa, CA facility in late January to meet with Onopchenko and other company reps. "He gained a better unde...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news